Turgunova L, Baidildina B, Laryushina Y, Koichubekov B, Turmukhambetova A, Akhmaltdinova L
Karaganda Medical University, Karaganda, Kazakhstan.
Cardiol Res Pract. 2020 Jun 23;2020:8020674. doi: 10.1155/2020/8020674. eCollection 2020.
Given the high rates of morbidity and mortality from cardiovascular disease (CVD), the primary and secondary CVD prevention is one of the public health priority. Inflammation and endothelial dysfunction are the major drivers of atherosclerosis development and progression. In this regard, the study of the biomarker application as a tool to better identify high-risk individuals is an up-to-date sector of modern cardiology. The simultaneous measurement of multiple biomarkers can increase the risk stratification for people who are not known to have cardiovascular events in their history. The study aimed to investigate the predictive value of chemokine (C-X-C motif) ligand 16 (CXCL16), endocan, and heart-type fatty acid binding protein (H-FABP) in the cardiovascular event development in people who are not known to have cardiovascular events in their history.
We examined 363 people aged 30 to 65 who have been living permanently in the city of Saran, Karaganda region. The selected participants were people registered at a clinic at the city of Saran, who were screened between August and September 2014.
The follow-up period was 48 months (from August-September 2014 to November 2018). The results showed that CXCL16 ( < 0.001), endocan ( < 0.001), and H-FABP (=0.002) biomarker levels are significantly higher in outcome groups compared with those of the no-outcome group. Univariate regression analysis proved the prognostic significance of all biomarkers in cardiovascular events development. The multivariate regression analysis after the adjustment confirmed that the CXCL16 increase was associated with the "composite endpoint" (CE) development ( < 0.001) while the endocan increased due to the development of major cardiovascular events (MACE) (=0.008); we did not find the association of the risks of event development with the H-FABP level increase (=0.83).
鉴于心血管疾病（CVD）的高发病率和死亡率，CVD的一级和二级预防是公共卫生重点之一。炎症和内皮功能障碍是动脉粥样硬化发生和发展的主要驱动因素。在这方面，研究生物标志物作为更好识别高危个体的工具是现代心脏病学的一个最新领域。同时测量多种生物标志物可提高对既往无心血管事件病史人群的风险分层。本研究旨在调查趋化因子（C-X-C基序）配体16（CXCL16）、内皮糖蛋白和心型脂肪酸结合蛋白（H-FABP）对既往无心血管事件病史人群发生心血管事件的预测价值。
我们检查了363名年龄在30至65岁之间、长期居住在卡拉干达地区萨兰市的人。所选参与者是在萨兰市一家诊所登记的人员，他们于2014年8月至9月接受了筛查。
随访期为48个月（从2014年8月至9月至2018年11月）。结果显示，与无事件组相比，结局组的CXCL16（<0.001）、内皮糖蛋白（<0.001）和H-FABP（=0.002）生物标志物水平显著更高。单因素回归分析证明了所有生物标志物在心血管事件发生中的预后意义。调整后的多因素回归分析证实，CXCL16升高与“复合终点”（CE）发生相关（<0.001），而内皮糖蛋白升高与主要心血管事件（MACE）发生相关（=0.008）；我们未发现事件发生风险与H-FABP水平升高之间存在关联（=0.83）。
